Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 showed TTI-101-equivalent exposure while improving tolerability. It also produced meaningful reductions in STAT3-driven disease-relevant immune cell populations, including Th17, T follicular helper (Tfh), and B cells.

Analysis

TTI-109 showed TTI-101-equivalent exposure while improving tolerability. It also produced meaningful reductions in STAT3-driven disease-relevant immune cell populations, including Th17, T follicular helper (Tfh), and B cells.